Vascular Surgery, University of Bologna "Alma Mater Studiorum", Policlinico S. Orsola Malpighi, IRCCS, Istituto di Ricovero e Cura a Carattere Scientifico, Bologna, Italy.
Vascular Surgery, University of Bologna "Alma Mater Studiorum", Policlinico S. Orsola Malpighi, IRCCS, Istituto di Ricovero e Cura a Carattere Scientifico, Bologna, Italy.
J Stroke Cerebrovasc Dis. 2022 Aug;31(8):106574. doi: 10.1016/j.jstrokecerebrovasdis.2022.106574. Epub 2022 Jun 23.
To report the characteristics of the prospective observational cohort study "Carotid Asymptomatic Stenosis (CARAS)", including patients with asymptomatic carotid stenosis under medical treatment and their first year of follow-up, in order to estimate the risk of cerebral ischemic events.
This is a prospective observational cohort study of CARAS>60% (Nascet criteria) patients, identified in a single duplex-ultrasonography (DUS) vascular laboratory (trail registration N: NCT04825080). Patient's enrollment started in January 2019 and ended in March 2020 with the follow-up conclusion scheduled in December 2025. The aimed sample size was calculated at 300 patients for a 5-year follow-up. The primary outcome were the incidence of ipsilateral neurologic ischemic events (stokes and transient ischemic attacks [TIA]), plaque progression rate, and survival. The follow-up was scheduled at six-month intervals for clinical visit and annually for DUS examination.
a total of 307 patients completed the first follow-up year. The mean age was 81±4 years, 55% were male. Contralateral stenosis >60% was present in 90 (29%) patients. Antiplatelet therapy and statins adherence was 80% and 88%, respectively. During the first year, 3 ispilateral strokes (1%) and 4 TIAs (1.3%) occurred, for a total of 2.3% ipsilateral ischemic events. During the first year, 43 (14%) plaques had a stenosis progression, which was correlated with the occurrence of neurological events (9.3% vs. 1.1%, P=.001, OR: 8.9; 95%CI: 1.9-41); 6 deaths (2%) occurred in the same period.
the preliminary one-year results of this prospective study suggest that the overall rate of any ipsilateral ischemic event, and specifically ipsilateral strokes, correlates with plaque progression.
报告前瞻性观察队列研究“颈动脉无症状狭窄(CARAS)”的特点,包括接受药物治疗的无症状颈动脉狭窄患者及其第一年的随访结果,以评估脑缺血事件的风险。
这是一项针对 CARAS>60%(Nascet 标准)患者的前瞻性观察队列研究,这些患者是在单一的双功能超声(DUS)血管实验室(试验注册号:NCT04825080)中确定的。患者的入组于 2019 年 1 月开始,2020 年 3 月结束,随访计划于 2025 年 12 月结束。预计样本量为 300 例,随访 5 年。主要结局为同侧神经缺血性事件(卒中和短暂性脑缺血发作[TIA])、斑块进展率和生存率的发生率。随访计划每 6 个月进行一次临床检查,每年进行一次 DUS 检查。
共有 307 例患者完成了第一年的随访。患者的平均年龄为 81±4 岁,55%为男性。90 例(29%)患者存在对侧狭窄>60%。抗血小板治疗和他汀类药物的依从性分别为 80%和 88%。在第一年中,同侧发生了 3 例卒中和 4 例 TIA,同侧缺血性事件的总发生率为 2.3%。在第一年中,43 例(14%)斑块发生了狭窄进展,这与神经事件的发生相关(9.3% vs. 1.1%,P=.001,OR:8.9;95%CI:1.9-41);同期有 6 例(2%)死亡。
这项前瞻性研究的初步一年结果表明,任何同侧缺血性事件的总体发生率,特别是同侧卒中和斑块进展相关。